JP2020039360A5 - - Google Patents

Download PDF

Info

Publication number
JP2020039360A5
JP2020039360A5 JP2019212012A JP2019212012A JP2020039360A5 JP 2020039360 A5 JP2020039360 A5 JP 2020039360A5 JP 2019212012 A JP2019212012 A JP 2019212012A JP 2019212012 A JP2019212012 A JP 2019212012A JP 2020039360 A5 JP2020039360 A5 JP 2020039360A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019212012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020039360A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020039360A publication Critical patent/JP2020039360A/ja
Publication of JP2020039360A5 publication Critical patent/JP2020039360A5/ja
Priority to JP2021052772A priority Critical patent/JP2021104030A/ja
Priority to JP2023025869A priority patent/JP2023062162A/ja
Priority to JP2024074883A priority patent/JP2024102229A/ja
Priority to JP2025112297A priority patent/JP2025143392A/ja
Ceased legal-status Critical Current

Links

JP2019212012A 2014-03-21 2019-11-25 抗egfr抗体及び抗体薬物コンジュゲート Ceased JP2020039360A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2021052772A JP2021104030A (ja) 2014-03-21 2021-03-26 抗egfr抗体及び抗体薬物コンジュゲート
JP2023025869A JP2023062162A (ja) 2014-03-21 2023-02-22 抗egfr抗体及び抗体薬物コンジュゲート
JP2024074883A JP2024102229A (ja) 2014-03-21 2024-05-02 抗egfr抗体及び抗体薬物コンジュゲート
JP2025112297A JP2025143392A (ja) 2014-03-21 2025-07-02 抗egfr抗体及び抗体薬物コンジュゲート

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968819P 2014-03-21 2014-03-21
US61/968,819 2014-03-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017501138A Division JP2017511376A (ja) 2014-03-21 2015-03-20 抗egfr抗体及び抗体薬物コンジュゲート

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021052772A Division JP2021104030A (ja) 2014-03-21 2021-03-26 抗egfr抗体及び抗体薬物コンジュゲート

Publications (2)

Publication Number Publication Date
JP2020039360A JP2020039360A (ja) 2020-03-19
JP2020039360A5 true JP2020039360A5 (https=) 2020-06-11

Family

ID=52997522

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2017501138A Ceased JP2017511376A (ja) 2014-03-21 2015-03-20 抗egfr抗体及び抗体薬物コンジュゲート
JP2019212012A Ceased JP2020039360A (ja) 2014-03-21 2019-11-25 抗egfr抗体及び抗体薬物コンジュゲート
JP2021052772A Ceased JP2021104030A (ja) 2014-03-21 2021-03-26 抗egfr抗体及び抗体薬物コンジュゲート
JP2023025869A Ceased JP2023062162A (ja) 2014-03-21 2023-02-22 抗egfr抗体及び抗体薬物コンジュゲート
JP2024074883A Ceased JP2024102229A (ja) 2014-03-21 2024-05-02 抗egfr抗体及び抗体薬物コンジュゲート
JP2025112297A Pending JP2025143392A (ja) 2014-03-21 2025-07-02 抗egfr抗体及び抗体薬物コンジュゲート

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017501138A Ceased JP2017511376A (ja) 2014-03-21 2015-03-20 抗egfr抗体及び抗体薬物コンジュゲート

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021052772A Ceased JP2021104030A (ja) 2014-03-21 2021-03-26 抗egfr抗体及び抗体薬物コンジュゲート
JP2023025869A Ceased JP2023062162A (ja) 2014-03-21 2023-02-22 抗egfr抗体及び抗体薬物コンジュゲート
JP2024074883A Ceased JP2024102229A (ja) 2014-03-21 2024-05-02 抗egfr抗体及び抗体薬物コンジュゲート
JP2025112297A Pending JP2025143392A (ja) 2014-03-21 2025-07-02 抗egfr抗体及び抗体薬物コンジュゲート

Country Status (22)

Country Link
US (7) US9493568B2 (https=)
EP (2) EP3126006A1 (https=)
JP (6) JP2017511376A (https=)
KR (3) KR20160138177A (https=)
CN (5) CN110841074B (https=)
AR (2) AR099812A1 (https=)
AU (4) AU2015231001A1 (https=)
CA (1) CA2942101A1 (https=)
CL (3) CL2016002359A1 (https=)
CR (2) CR20210097A (https=)
DO (2) DOP2016000252A (https=)
EC (1) ECSP16082556A (https=)
IL (2) IL295906A (https=)
MX (2) MX385853B (https=)
PE (2) PE20161211A1 (https=)
PH (2) PH12021552141A1 (https=)
RU (2) RU2020124944A (https=)
SG (3) SG10201808837RA (https=)
TW (5) TW202214691A (https=)
UA (1) UA125575C2 (https=)
UY (1) UY36041A (https=)
WO (1) WO2015143382A1 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
JP6592426B2 (ja) 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
AR099812A1 (es) * 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US10604740B2 (en) 2014-05-14 2020-03-31 Carsgen Therapeutics Limited Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein
JP6214790B2 (ja) * 2014-09-16 2017-10-18 イース チャーム リミテッド 抗egfr抗体および同抗体の使用法
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
KR101776238B1 (ko) * 2015-06-12 2017-09-12 사회복지법인 삼성생명공익재단 교모세포종 환자에서 이브루티닙 감수성과 관련된 유전자 및 그 용도
CN116059395A (zh) * 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
EP3368056B1 (en) * 2016-01-26 2025-08-20 Raghoottama Pandurangi Compositions and methods for sensitizing low responsive tumors to cancer therapy
CN108602879A (zh) * 2016-02-04 2018-09-28 倪劲松 用于治疗疾病的抗体-药物协同作用技术
JP2019513371A (ja) * 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
BR112018075639A2 (pt) * 2016-06-08 2019-04-09 Abbvie Inc. conjugados de anticorpo fármaco anti-egfr
AU2017277534A1 (en) * 2016-06-08 2019-01-03 Abbvie Inc. Anti-EGFR antibody drug conjugates
RU2018147224A (ru) * 2016-06-08 2020-07-14 Эббви Инк. Конъюгаты антитела к egfr и лекарственного средства
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
CN107522785B (zh) * 2016-06-22 2020-05-08 北京大学 抗egfr突变体iii单克隆抗体、制备方法及其应用
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
WO2018006785A1 (zh) * 2016-07-05 2018-01-11 江苏恒瑞医药股份有限公司 Egfr抗体-药物偶联物及其在医药上的应用
MY192158A (en) 2016-09-14 2022-08-03 Abbvie Biotherapeutics Inc Anti-pd-1 antibodies and their uses
JP2020533269A (ja) * 2016-12-14 2020-11-19 デベロップメント センター フォー バイオテクノロジー 抗体−薬物複合体およびその使用
JP2020526584A (ja) * 2017-06-28 2020-08-31 ザ ロックフェラー ユニバーシティー 抗mertkアゴニスト抗体−薬物コンジュゲートおよびその使用
MX2020000903A (es) * 2017-08-11 2020-07-22 Genentech Inc Anticuerpos anti-cd8 y usos de los mismos.
WO2019046858A1 (en) * 2017-09-02 2019-03-07 Abbvie Inc. ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF
WO2019046859A1 (en) * 2017-09-02 2019-03-07 Abbvie Inc. ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF
JP7429639B2 (ja) 2017-11-18 2024-02-08 マガリャエス,ンゾラ デ 抗体薬物複合体またはその薬学的に許容される塩
EP3753952A4 (en) * 2017-12-13 2022-04-13 XDCExplorer (Shanghai) Co., Ltd. EGFRVIII ANTIBODY AND CONJUGATE, AND METHODS FOR ITS PRODUCTION AND USE
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
SG11202006510XA (en) * 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
EP3746079A1 (en) * 2018-01-31 2020-12-09 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
WO2019157454A1 (en) 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
BR112020018492A2 (pt) * 2018-03-14 2020-12-29 Affimed Gmbh Proteína de ligação ao antígeno egfr/cd16 biespecífica
CA3095757A1 (en) * 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
AR114789A1 (es) * 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
WO2019211708A1 (en) * 2018-05-04 2019-11-07 Kashiv Biosciences, Llc Stable pharmaceutical compositions of dianhydrogalactitol
EP3818085A4 (en) 2018-06-01 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
CA3106403A1 (en) 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
EP3826673A4 (en) * 2018-07-26 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND METHODS FOR IMAGING
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
CN109200291B (zh) * 2018-10-24 2021-06-08 中国医学科学院医药生物技术研究所 一种靶向于egfr的抗体偶联药物及其制备方法和其用途
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
US11478553B2 (en) 2019-02-15 2022-10-25 Wuxi Biologies Ireland Limited Process for preparing antibody-drug conjugates with improved homogeneity
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
WO2020210768A1 (en) * 2019-04-12 2020-10-15 The Trustees Of The University Of Pennsylvania Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
CN110845623B (zh) * 2019-10-11 2021-07-09 厦门大学 一种egfr特异性嵌合抗原受体及其应用
KR102842684B1 (ko) * 2019-12-30 2025-08-05 브리스타 이뮤노테크 리미티드 향상된 t-세포 수용체 star 및 이의 적용
EP4144764A4 (en) * 2020-04-28 2024-07-17 Sinocelltech Ltd. TRUNCATED EXTRACELLULAR DOMAIN MOLECULE TGFßR2, FUSION PROTEIN OF TRUNCATED EXTRACELLULAR DOMAIN MOLECULE TGFßR2 AND ANTI-EGFR ANTIBODY, AND ANTITUMORAL USE OF FUSION PROTEIN
KR20230043118A (ko) * 2020-06-24 2023-03-30 사프렘 테크놀로지스 비.브이. 사포닌 및 단일-도메인 항체의 접합체, 상기 접합체를 포함하는 약학적 조성물, 이의 치료 용도
EP4117731A1 (en) * 2020-06-24 2023-01-18 Sapreme Technologies B.V. Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
EP4192874A1 (en) 2020-08-05 2023-06-14 Dragonfly Therapeutics, Inc. Antibodies targeting egfr and use thereof
JP2023545681A (ja) 2020-09-30 2023-10-31 インスティテュート オブ ズーオロジー、チャイニーズ アカデミー オブ サイエンシーズ Egfrを標的とするキメラ抗原受容体
CN112442355B (zh) * 2020-11-28 2022-04-05 江西师范大学 一种稀土-透明质酸配位聚合物包覆的vs2纳米结构及其制备方法和应用
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
AU2022267410A1 (en) * 2021-04-26 2023-11-09 Myrio Therapeutics Pty Ltd EGFRvIII BINDING PROTEINS
US20230027739A1 (en) 2021-05-10 2023-01-26 Entrada Therapeutics, Inc. Antigen-binding and antigen degradation constructs
CN114044826B (zh) * 2021-10-12 2023-11-17 南京融捷康生物科技有限公司 针对EGFRvIII的单域抗体及其衍生蛋白和应用
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
TW202434307A (zh) 2023-01-18 2024-09-01 大陸商泰勵生物科技(上海)有限公司 抗體偶聯藥物及其用途
CN117659203B (zh) * 2023-12-06 2024-08-13 科弈(浙江)药业科技有限公司 一种抗met/egfr双特异性抗体及其药物偶联物
WO2026082020A1 (zh) * 2024-10-15 2026-04-23 一线医药(杭州)有限公司 双特异性抗体和药物偶联物及其用途

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US938A (en) 1838-09-22 Improvement in paddle-wheels for propelling boats
US4526A (en) 1846-05-16 Improvement in the mode o
US319A (en) 1837-07-31 Improvement in machines for breaking and dressing hemp and flax
US8236A (en) 1851-07-22 Hanging cakriage-body
US4434150A (en) 1981-10-19 1984-02-28 Ortho Diagnostic Systems, Inc. Immunological reagents employing polymeric backbone possessing reactive functional groups
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5157049A (en) 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
WO1991016350A1 (en) 1990-04-20 1991-10-31 Ludwig Institute For Cancer Research Aberrant, epidermal growth factor receptor dna, rna and protein forms and method
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
ATE194767T1 (de) 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5380751A (en) 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994016729A1 (en) 1993-01-28 1994-08-04 Neorx Corporation Targeted nitric oxide pathway or nitric oxide synthase modulation
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5433364A (en) 1993-02-19 1995-07-18 Dynetics Engineering Corporation Card package production system with burster and carrier verification apparatus
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
WO1995015770A1 (en) 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
IT1275043B (it) 1994-07-21 1997-07-29 Agerbioss Snc Di Zanin R & C Metodo e relativo prodotto per la difesa delle piante dai parassiti vegetali
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
WO1996016988A1 (en) 1994-11-28 1996-06-06 Thomas Jefferson University Reagents and processes for targeting mutant epidermal growth factor receptors
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5840929A (en) 1995-04-14 1998-11-24 Bristol-Myers Squibb Company C4 methoxy ether derivatives of paclitaxel
US5705503A (en) 1995-05-25 1998-01-06 Goodall; Brian Leslie Addition polymers of polycycloolefins containing functional substituents
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
WO1997007788A2 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0871490T3 (da) 1995-12-22 2003-07-07 Bristol Myers Squibb Co Forgrenede hydrazonlinkere
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
IT1282692B1 (it) 1996-02-27 1998-03-31 San Raffaele Centro Fond Citochine modificate per l'uso in terapia
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
AU3740997A (en) 1996-08-26 1998-03-19 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
US5773464A (en) 1996-09-30 1998-06-30 Bristol-Myers Squibb Company C-10 epoxy taxanes
AU4966597A (en) 1996-11-19 1998-06-10 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
JP2001511811A (ja) 1997-02-13 2001-08-14 ボーン ケア インターナショナル インコーポレイテッド ビタミンd化合物の標的治療放出
WO1998036765A1 (en) 1997-02-25 1998-08-27 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
US6555367B1 (en) 1997-10-10 2003-04-29 The United States Of America As Represented By The Department Of Health And Human Services Complex of biotinylated viral vector and ligand for targeted gene delivery
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CN1269087C (zh) 1999-07-31 2006-08-09 朴奎珍 使用数字音频和字幕数据的学习方法和装置
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
WO2001090198A1 (en) 2000-05-24 2001-11-29 Ludwig Institute For Cancer Research Multicomponent conjugates which bind to target molecules and stimulate cell lysis
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2002311919B8 (en) 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040028687A1 (en) 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
CA2482967A1 (en) 2002-05-01 2003-11-13 Trellis Bioscience, Inc. Binary or polynary targeting and uses thereof
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
KR20130065723A (ko) * 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP1718323B1 (en) 2004-02-20 2011-12-07 The Trustees of The University of Pennsylvania Binding peptidomimetics and uses of the same
WO2005085251A1 (en) 2004-03-01 2005-09-15 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
US20050226882A1 (en) 2004-04-08 2005-10-13 Awdalla Essam T Method and multicomponent conjugates for treating cancer
AU2005233387B2 (en) 2004-04-15 2011-05-26 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
AU2005294214A1 (en) 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use
US7263946B2 (en) 2004-11-01 2007-09-04 Craig Worthy System for measuring chain or rope deployment
EP1695717A1 (en) 2005-02-23 2006-08-30 Ludwig-Maximilians-Universität Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
US7612062B2 (en) 2005-04-21 2009-11-03 Spirogen Limited Pyrrolobenzodiazepines
US7447597B2 (en) 2005-05-06 2008-11-04 Exxonmobil Research And Engineering Company Data processing/visualization method for two (multi) dimensional separation gas chromatography xmass spectrometry (GCxMS) technique with a two (multiply) dimensional separation concept as an example
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
CA2690973A1 (en) 2006-06-23 2007-12-27 Paul M. Simon Targeted immune conjugates
CA2664327A1 (en) 2006-09-15 2008-03-20 Lifescience Pharmaceuticals Method for detecting and treating skin disorders
US7598028B2 (en) 2006-11-28 2009-10-06 The Regents Of The University Of Michigan Compositions and methods for detecting and treating prostate disorders
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑
KR20090114430A (ko) 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 dcir에 대한 항원 표적화에 기초한 백신
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Erbb3에 대한 항체 및 이의 용도
NZ595319A (en) 2007-02-23 2012-09-28 Baylor Res Inst Activation of human antigen-presenting cells through clec-6
EP2132226B1 (en) 2007-02-23 2019-03-27 Baylor Research Institute Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック, インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP1985633A1 (en) * 2007-04-26 2008-10-29 LFB Biotechnologies Kit of parts for the treatment of cancer or infectious diseases
US20110159018A1 (en) 2007-05-03 2011-06-30 Medizinische Universitat Innsbruck Complement factor h-derived short consensus repeat-antibody constructs
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
TWI478937B (zh) 2008-01-15 2015-04-01 Abbvie Inc 改良之哺乳動物表現載體及其用途
FR2931243A1 (fr) 2008-05-14 2009-11-20 Inst Francais Du Petrole Procede pour determiner des proprietes physico-chimiques d'un echantillon petrolier a partir de chromatographie en phase gazeuse bidimensionnelle
US20090285757A1 (en) 2008-05-16 2009-11-19 Northeastern University Methods of targeting cells for diagnosis and therapy
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US8309093B2 (en) 2009-03-06 2012-11-13 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
EP2411413B1 (en) 2009-03-23 2016-05-11 Quark Pharmaceuticals, Inc. Compounds compositions and methods of treating cancer and fibrotic diseases
DE102009026075A1 (de) 2009-06-30 2011-01-05 Röhm Gmbh Bohrvorrichtung
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2011057216A1 (en) 2009-11-06 2011-05-12 The Pennsylvania State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
GB0919751D0 (en) 2009-11-11 2009-12-30 King S College Hospital Nhs Fo Conjugate molecule
US20110217363A1 (en) 2010-03-05 2011-09-08 Bionanox Two-step targeted tumor therapy with prodrug encapsulated in nanocarrier
CA2795349C (en) 2010-04-15 2016-11-29 Seattle Genetics, Inc. Targeted pyrrolobenzodiazepine conjugates
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
BR112012031727B1 (pt) * 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
MX347954B (es) * 2010-09-29 2017-05-19 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
EA201390472A1 (ru) * 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2856411A1 (en) * 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
JP6647868B2 (ja) 2013-02-20 2020-02-14 ノバルティス アーゲー ヒト化抗EGFRvIIIキメラ抗原受容体を用いたがんの処置
CN105283201B (zh) * 2013-03-14 2019-08-02 斯克利普斯研究所 靶向剂抗体偶联物及其用途
EP2968589A1 (en) 2013-03-15 2016-01-20 AbbVie Inc. Antibody drug conjugate (adc) purification
MX2015012549A (es) 2013-03-15 2016-06-21 Abbvie Deutschland Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
CN105814083A (zh) * 2013-10-15 2016-07-27 加州生物医学研究所 嵌合抗原受体t细胞开关和其用途
AR099812A1 (es) * 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr

Similar Documents

Publication Publication Date Title
JP2020039360A5 (https=)
JP2022031635A5 (https=)
JP2018046872A5 (https=)
JP2023166395A5 (https=)
JP2021191763A5 (https=)
Both et al. Monoclonal antibodies for prophylactic and therapeutic use against viral infections
JP2020508655A5 (https=)
HRP20181069T1 (hr) Antagonistička protutijela na il-17
JP2014533659A5 (https=)
JP2014519334A5 (https=)
JP2020514277A5 (https=)
JP2017052784A5 (https=)
JP2009532336A5 (https=)
JP2020055849A5 (https=)
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use
NZ718973A (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2019504032A5 (https=)
SI2699264T1 (en) Antibodies and other molecules that bind b7-h1 and pd-1
JP2020519308A5 (https=)
RU2018137110A (ru) Антитела против psma и их применение
RU2015149617A (ru) Моноклональные антитела против клаудина-18 для лечения рака
JP2009225799A5 (https=)
JP2016533763A5 (ja) ヒトpd−1に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物